Please provide your email address to receive an email when new articles are posted on . Rezpegaldesleukin is a first-in-class interleukin-2 receptor agonist that proliferates and activates regulatory ...
The use of interleukin-2 (IL-2)-directed therapies has been associated with systemic toxicities, regulatory T cell (Treg) activation and limited efficacy so far. Researchers from Regeneron ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results